Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266899 | 1.00 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL2556418 | 1.00 | HTR2A (0.75) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL1740902 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL31545209 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL1740903 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL3460220 | 0.86 | HTR2A (1.00) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| SCHEMBL3027061 | 0.85 | APLNR (0.59) | HTR2A | |
| Hydrochloric Acid SCHEMBL29542459 | 0.84 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL3486527 | 0.84 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 | |
| Hydrochloric Acid SCHEMBL30861235 | 0.84 | HTR2A (0.97) | HTR2AHTR1AHTR2CHTR2BTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | claimed |
| EP-4720030-A1 | ASYMMETRIC PHENYLALKYLAMINES | Alexander Shulgin Research Institute, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | Kuleon, LLC (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | KULEON LLC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2025024400-A2 | SUBSTITUTED TRYPTAMINES AND USES THEREOF | 2A BIOSCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024251807-A1 | COMPANION ANIMAL TREATMENTS | CYBIN IRL LIMITED (IE) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024243599-A1 | ASYMMETRIC PHENYLALKYLAMINES | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| EP-4452986-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | Kuleon LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024178425-A1 | HYDROXYALKYL AND METHOXYALKYL TRYPTAMINES | 2A BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| CN-118234491-A | Hallucinogen-fatty acid combinations | 明德赛特制药公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2024108195-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024091523-A1 | CONFORMATIONALLY RESTRICTED PHENETHYLAMINE ANALOGS | 2A BIOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-117715632-A | Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof | 恩赛斯生物科学股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023225043-A1 | TRICYCLIC AND TETRACYCLIC SEROTONIN RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023122135-A1 | SEROTONIN RECEPTOR AGONISTS AND METHODS OF MAKING AND USING THE SAME | KULEON LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023023298-A1 | HALLUCINOGENIC AND NON-HALLUCINOGENIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PSILOSTERICS, LLC (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282722-A1 | 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR1A 3/4885HTR2C 2/4885 |
| US-12441683-B2 | 7-methyl indole analogs and dosage forms containing the same | HTR7, HTR2C, HTR1A | HTR2A 8/4885HTR1A 3/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.